18-[[(1S)-1-carboxy-4-[2-[2-[2-[2-[2-[2-[[(2S)-4-carboxy-1-oxobutan-2-yl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-4-oxobutyl]amino]-18-oxooctadecanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 18-[[(1S)-1-carboxy-4-[2-[2-[2-[2-[2-[2-[[(2S)-4-carboxy-1-oxobutan-2-yl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-4-oxobutyl]amino]-18-oxooctadecanoic acid
• 化学式: C₄₀H₇₀N₄O₁₅
• 分子量: 847.0
• InChiKey: RSKCBPDNUHOYSM-LQJZCPKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  59
• 可旋转键数：
  43
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  282
• 氢给体数：
  7
• 氢受体数：
  15

文献信息

• EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
  申请人：HAACK Torsten

  公开号：US20140100156A1

  公开（公告）日：2014-04-10

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
• DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS
  申请人：Sanofi

  公开号：US20140221281A1

  公开（公告）日：2014-08-07

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
• US9181305B2
  申请人：——

  公开号：US9181305B2

  公开（公告）日：2015-11-10
• US9745360B2
  申请人：——

  公开号：US9745360B2

  公开（公告）日：2017-08-29